Novo Nordisk Stakeholder Reports $9 Billion In Income Due To Robust Weight Loss Drug Sales

Novo Holdings, the controlling shareholder of weight loss drugmaker Novo Nordisk A/S (NYSE:NVO), reported Wednesday income and investment returns of 60 billion Danish kroner (around $8.68 billion) for 2024.

Novo Holdings owns 28.1% shares in Novo Nordisk.

Dividends and the share repurchase programs of the Novo Group companies (Novo Nordisk and Novonesis) totaled 23 billion Danish kroner, and Returns from the Investment Portfolio generated an income of 37 billion Danish kroner.

In the fourth quarter of 2024, Ozempic sales increased 12% to 33.85 billion Danish kroner, and Wegovy sales more than doubled to 19.87 billion Danish kroner.

Also Read: Novo Nordisk Shares Data From Injectable Ozempic, Oral Weight Loss Drug

Novo Holdings CEO Kasim ...

https://www.benzinga.com/general/health-care/25/04/44606000/novo-nordisk-largest-shareholder-novo-holdings-reports-around-9-billion-in-income-boosted-by-